RxDoctor Payments Data

Meng Zhou Wang

Clinical Neurophysiology · Greenville, SCNPI 1023088002

Payments from drug & device makers

$6,023in general payments, 2019–2025

Across 378 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$871
  • AbbVie$866
  • Teva Pharmaceuticals USA, Inc.$705
  • Biohaven Pharmaceuticals, Inc.$444
  • Biohaven Pharmaceutical Holding Company Ltd.$376
  • Novartis$330
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$5,95699%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant12$15,558
Zonisamide26$920
Levetiracetam29$772
Gabapentin19$379
Lamotrigine16$170
Topiramate12$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$866$15,55812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Greenville

Where these figures come from

Is this you, or does something look wrong? →